---
$id: https://graph.org.ai/products/commodity/51202407
$type: Product
source: UNSPSC
code: "51202407"
title: "Dacliximab or daclizumab"
class: "51202400"
classTitle: "Immunosupressant antibodies"
family: "51200000"
familyTitle: "Immunomodulating drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Dacliximab or daclizumab

**UNSPSC Code**: 51202407
**Class**: [Immunosupressant antibodies](Immunosupressant antibodies.mdx)
**Family**: [Immunomodulating drugs](../Immunomodulating drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a monoclonal antibody and immunosuppressant with the molecular formula C6394H9888N1696O2012S44, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CUJ2MVI71Y, more generally known as daclizumab. European Medicines Agency schedules daclizumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06885MIG. The term DACLIZUMAB is an International Non-Proprietary Name or INN. Dacliximab or daclizumab bears US NLM identifiers UMLS ID C0663182 and NCI Concept Code C1569. Most nations, for tariff and trade purposes, schedule dacliximab or daclizumab under 30021002 and SITC 54163. SMILES: NONE.

